Company Newron Pharmaceuticals S.p.A.

NWRN

IT0004147952

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Newron Pharmaceuticals S.p.A.

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals

Delayed Swiss Exchange Other stock markets 05:49:18 2024-04-16 am EDT			5-day change	1st Jan Change
7.33 ^CHF	-1.21%		-4.31%	+48.08%

Mar. 19	Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 19	Transcript : Newron Pharmaceuticals S.p.A., 2023 Earnings Call, Mar 19, 2024

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinsonâs disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Number of employees: 22

CHF in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Drugs 100.0 %	6	100.0 %	9	100.0 %	+43.85%

CHF in Million	2022	Weight	2023	Weight	Delta
Italy & United States 100.0 %	6	100.0 %	9	100.0 %	+43.85%

Managers	Title	Age	Since
Stefan Weber CEO	Chief Executive Officer	60	12-05-14
Luca Benatti FOU	Founder	63	97-12-31
Roberto Galli DFI	Director of Finance/CFO	-	01-12-31
Filippo Moriggia COO	Chief Operating Officer	-	16-10-31
Ravi Anand CTO	Chief Tech/Sci/R&D Officer	67	04-12-31
Laura Faravelli PRN	Corporate Officer/Principal	-	18-12-31
Dennis Dionne PRN	Corporate Officer/Principal	-	14-12-31

Members of the board	Title	Age	Since
Patrick J. Langlois BRD	Director/Board Member	78	07-12-31
Luca Benatti FOU	Founder	63	97-12-31
Ulrich Köstlin CHM	Chairman	71	12-12-31
Stefan Weber CEO	Chief Executive Officer	60	12-05-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,631,834	17,158,913 ( 92.09 %)	0	92.09 %

Name	Equities	%	Valuation
Gefim SpA 4.216 %	785,448	4.216 %	7 M CHF
Heights Capital Management, Inc. 4.025 %	750,000	4.025 %	6 M CHF
Tobias Scherer 2.990 %	557,091	2.990 %	5 M CHF
Corisol Holding AG 0.2966 %	55,254	0.2966 %	476 042 CHF
Mirabaud & Cie SA 0.2898 %	54,000	0.2898 %	465 238 CHF
IFS Independent Financial Services AG 0.2234 %	41,619	0.2234 %	358 569 CHF
DWS CH AG 0.0920 %	17,134	0.0920 %	147 618 CHF
Baloise Asset Management AG 0.0905 %	16,858	0.0905 %	145 240 CHF
Feri (Schweiz) AG 0.0870 %	16,218	0.0870 %	139 727 CHF
Brandford Trust SA 0.0805 %	15,000	0.0805 %	129 233 CHF

Newron Pharmaceuticals SpA

via Antonio Meucci 3

20091, Bresso

+39 02 610 3461

https://www.newron.com/

address Newron Pharmaceuticals S.p.A.(NWRN)

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.64 EUR

Average target price

13.28 EUR

Spread / Average Target

+73.84%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
NEWRON PHARMACEUTICALS S.P.A.	+49.90%	157M
CSL LIMITED	-2.83%	88.12B
SAMSUNG BIOLOGICS CO.,LTD.	+4.34%	40.6B
BIOGEN INC.	-23.95%	28.81B
UCB	+51.39%	24.35B
BIOMARIN PHARMACEUTICAL INC.	-5.09%	17.5B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-32.11%	13.54B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-5.10%	13.52B
INCYTE CORPORATION	-14.91%	12.09B
SWEDISH ORPHAN BIOVITRUM AB	-4.79%	7.88B

Biopharmaceuticals